Ethical considerations in presymptomatic testing for variant CJD

Journal of Medical Ethics

Volumn 31, Issue 11, 2005, Pages 625-630

  Duncan, R E ^a,b   Delatycki, M B ^a,b   Collins, S J ^b   Boyd, A ^b   Masters, C L ^b   Savulescu, Julian ^a,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL PROTOCOL; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE CARRIER; DISEASE TRANSMISSION; EPIDEMIC; FATALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; MEDICAL ETHICS; NON INVASIVE MEASUREMENT; ORGAN DONOR; PRACTICE GUIDELINE; RELIABILITY; SCREENING TEST; SURGICAL PATIENT; ZOONOSIS;

HEALTH CARE AND PUBLIC HEALTH;

ANIMALS; CATTLE; CLINICAL PROTOCOLS; CREUTZFELDT-JAKOB SYNDROME; DECONTAMINATION; DISEASE OUTBREAKS; ETHICS, CLINICAL; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; HUNTINGTON DISEASE; PRIONS; ZOONOSES;

EID: 28244485975     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2005.011965     Document Type: Article

References (47)

1. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
2. Collinge J, Sidle KCL, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996;383:685-90.
3. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997;389:498-501.
4. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-50.
5. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004;363:51-61.
6. Minor PD. Technical aspects of the development and validation of tests for variant Creutzfeldt-Jakob disease in blood transfusion. Vox Sanguinis 2004;86:164-70.
7. Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171-80.
8. Bernoulli C, Siegfreid J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;i:478-9.
9. Fichet G, Comoy E, Duval C, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004;364:521-6.
10. Trevitt CR, Singh PN. Variant Creutzfeldt-Jakob disease: pathology, epidemiology, and public health implications. Am J Clin Nutr 2003;78(suppl):651S-6S.
11. Brown P, Preece M, Brandel J-P, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-81.
12. Safar J, Wille H, Itri V, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998;4:1157-65.
13. Bonn D. Future uncertain for reliable vCJD screening tests. Lancet 2000;356:228.
14. British Broadcasting Corporation. We may have a test for vCJD [BBC News]. 16 March 2004. http://news.bbc.co.uk/go/pr/fr/-/hi/health/3517184.stm (accessed 18 Mar 2004).
15. Blajchman MA, Goldman M, Webert KE, et al. Proceedings of a consensus conference: the screening of blood donors for variant CJD. Transfus Med Rev 2004;18:73-92.
16. The National Creutzfeldt-Jakob Disease Surveillance Unit. CJD figures, Update 6 Dec 2004.http://.www.cjd.ed.ac.uk (accessed 8 Dec 2004) [For specific up to date figures, http://www.cjd.ed.ac.uk/figures.htm].
17. Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21.
18. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527-9.
19. Bird SM. Recipients of blood or blood products "at vCJD risk". BMJ 2004;328:118-9.
20. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004;203:733-9.
21. Wells GA, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987;31:419-20.
22. Tan L, Williams MA, Khan MK, et al. Risk of transmission of bovine spongiform encephalopathy to humans in the United States: Report of the council of scientific affairs. JAMA 1999;281:2330-9.
23. Lord Phillips of Worth Matravers, Bridgeman J, Ferguson-Smith M. The BSE Inquiry: the inquiry into BSE and variant CJD in the United Kingdom. Oct 2000. http://www.bseenquiry.gov.uk/index.htm (accessed 8 Jan 2005).
24. Almond J, Pattison J. Human BSE. Nature 1997;389:437-8.
25. Brown P. On the origins of BSE [Commentary]. Lancet 1998;352:252-3.
26. Mishra RS, Basu S, Gu Y, et al. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J Neurosci 2004;24:11280-90.
27. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001;24:519-50.
28. Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575-82.
29. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-9.
30. Horby P. Variant Creutzfeldt-Jakob disease: an unfolding epidemic of misfolded proteins. J Paediatr Child Health 2002;38:539-42.
31. McDonnell G, Burke P. The challenge of prion decontamination. Clin Infect Dis 2003;36:1152-4.
32. Hunter M. Inquiry into handling of CJD alert welcomed. BMJ 2002;325:1055.
33. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999;354:317-23.
34. Sneath PHA. Estimation of the size of the vCJD epidemic. Antonie can Leeuwenhoek 2004;86:93-103.
35. Kmietowicz Z. Patients informed of increased risk of vCJD contact. BMJ 2004;329:702.
36. Spinney L. vCJD epidemic could be first of many, experts warn [News]. Nat Med 2003;9:1096.
37. Frosh A, Smith LC, Jackson CJ, et al. Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet 2004;364:1260-2.
38. Myers R, Marans K, MacDonald M. Huntington's disease. In: Wells R, Warren S, eds. Genetic instabilities and hereditary neurological diseases. San Diego, CA: Academic Press, 1998:301-23.
39. Delatycki MB, Tassicker R. Adult onset neurological disorders: predictive genetic testing. Aust Fam Physician 2001;30:948-52.
40. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994;31:555-9.
41. Binedell J, Soldan JR, Harper PS. Predictive testing for Huntington's disease: predictors of uptake in South Wales. Clin Genet 1998;54:477-88.
42. Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalisation after predictive testing for Huntington disease. Am J Hum Genet 1999;64:1293-304.
43. Bird T. Outrageous fortune: the risk of suicide in genetic testing for Huntington disease. Am J Hum Genet 1999;64:1289-92.
44. Sobel SK, Cowan DB. Impact of genetic testing for Huntington disease on the family system. Am J Med Genet 2000;90:49-59.
45. Meiser B, Dunn S. Psychological effects of genetic testing for Huntington's disease: an update of the literature. West J Med 2001;174:336-40.
46. Human Genetics Commission (UK). Inside information: balancing interests in the use of personal genetic data. 2002. http://www.hgc.gov.uk (accessed 1 Feb 2005).
47. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004;364:529-31.